An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021.
Food and Drug Administration
warning letters
Journal
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
13
12
2022
revised:
29
07
2023
accepted:
21
08
2023
medline:
28
11
2023
pubmed:
26
9
2023
entrez:
25
9
2023
Statut:
ppublish
Résumé
We aimed to ascertain the frequency and types of Food and Drug Administration (FDA)-identified clinical outcome assessment (COA) violations in US pharmaceutical promotional materials from 2013 to 2021 by updating the review by Symonds et al (covering the period 2006-2012 for patient-reported outcomes [PRO] measures), expanding to infringements across all types of COAs, and grouping by efficacy or overall patient experience. Warning letters (WLs) and untitled letters (ULs) issued by the FDA's Office of Prescription Drug Promotion were reviewed for COA violations and classified by their type: (1) COA measure not fit for purpose, (2) issue with study design or interpretation of results, and (3) inadequate statistical analysis. From 2013 to 2021, the FDA issued 22 WLs and 65 ULs. Year 2013 showed the highest number of letters issued (n = 24). Of the total 87 letters reviewed, 22 (25%) contained a COA violation, consisting of 6 WLs (27%) and 16 ULs (25%), including 20 (23%) with a PRO-related violation. The most common violations cited "study design or interpretation of results" (21 of 22 [95%]). Overall, the absolute number of WLs and ULs issued declined when comparing 2006 to 2012 with 2013 to 2021. Despite the overall reduction, this review still identified 25% of letters citing COA infringements (23% with PRO issues), which was similar to the prior review (19% PRO infringements). This may be due to increased FDA attention to patient-focused drug development.
Identifiants
pubmed: 37748736
pii: S1098-3015(23)03130-3
doi: 10.1016/j.jval.2023.08.012
pii:
doi:
Substances chimiques
Prescription Drugs
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1675-1680Informations de copyright
Copyright © 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Author Disclosures Ms Sams and Dr Symonds are employees of Clinical Outcomes Solutions and reported receiving funds from Gilead Sciences. Dr Slagle reported receiving consulting fees from Gilead Sciences. Dr Antonova is a Former employee of Gilead Sciences. Dr Globe is a full-time employee of Gilead Sciences and reported receiving stock as an employment benefit. No other disclosures were reported.